nature medicine VOLUME 16 | NUMBER 2 | FEBRUARY 2010 2 1 9 l e t t e r s Lung cancer is the leading cause of cancer death worldwide 1 . Recent data suggest that tumor-associated inflammatory cells may modify lung tumor growth and invasiveness 2,3 . To determine the role of neutrophil elastase (encoded by Elane) on tumor progression, we used the loxP-Stop-loxP K-ras G12D (LSL-K-ras) model of mouse lung adenocarcinoma 4 to generate LSL-K-ras-Elane −/− mice. Tumor burden was markedly reduced in LSL-K-ras-Elane −/− mice at all time points after induction of mutant K-ras expression. Kaplan-Meier survival analysis showed that whereas all LSL-K-ras-Elane +/+ mice died, none of the mice lacking neutrophil elastase died. Neutrophil elastase directly induced tumor cell proliferation in both human and mouse lung adenocarcinomas by gaining access to an endosomal compartment within tumor cells, where it degraded insulin receptor substrate-1 (IRS-1). Immunoprecipitation studies showed that, as neutrophil elastase degraded IRS-1, there was increased interaction between phosphatidylinositol 3-kinase (PI3K) and the potent mitogen platelet-derived growth factor receptor (PDGFR), thereby skewing the PI3K axis toward tumor cell proliferation. The inverse relationship identified between neutrophil elastase and IRS-1 in LSL-K-ras mice was also identified in human lung adenocarcinomas, thus translating these findings to human disease. This study identifies IRS-1 as a key regulator of PI3K within malignant cells. Additionally, to our knowledge, this is the first description of a secreted proteinase gaining access to the inside of a cell and altering intracellular signaling.
Lung cancer is the leading cause of cancer-related deaths worldwide, with dismal ~15% five-year survival rates despite therapeutic advances over the past few decades 1 . A better understanding of tumor-associated inflammation may identify new therapeutic targets.
Neutrophils are known to infiltrate tumors; however, only recently have they been thought to modify tumor growth and invasiveness [2] [3] [4] [5] [6] [7] [8] . We have previously shown that lung cancer cells elaborate CXC chemokines driving neutrophil recruitment. Hence, tumor-associated neutrophils do not necessarily represent a means of host defense. Indeed, there have been reports that neutrophil infiltrates within tumors correlate with poor clinical outcomes 9, 10 .
The purpose of this study was to determine whether the most potent neutrophil proteinase, neutrophil elastase, has a role in tumor progression. Neutrophil elastase is a neutrophil-specific serine proteinase with broad substrate specificity. Its expression is limited to the promyelocyte stages of bone marrow development, where it is packaged into azurophil granules 11 . The main function of neutrophil elastase is to eliminate pathogens within neutrophils 12, 13 . However, upon activation, neutrophils translocate neutrophil elastase to the cell surface and secrete small amounts of the enzyme from individual granules 14 .
We subjected LSL-K-ras-Elane −/− and control (LSL-K-ras-Elane +/+ ) mice to 5 × 10 6 plaque-forming units of intratracheal adenoviral Cre recombinase (AdenoCre) to activate mutant K-ras expression 4 . During the 28 weeks after AdenoCre administration, all LSL-K-ras-Elane +/+ mice, but none of the LSL-K-ras-Elane −/− mice, died ( Fig. 1a) . Survival analysis showed a significant (P = 0.006) advantage for LSL-K-ras-Elane −/− mice. Neutrophil elastase deficiency is not completely protective, as we have subsequently identified death beyond 30 weeks in independent studies (data not shown). Tumor burden was markedly reduced in LSL-K-ras-Elane −/− mice at all time points (Fig. 1) . The differences observed represent a reduction in tumor growth and differentiation (less mature lesions), as tumor number was equivalent in the two groups ( Supplementary Table 1 ). We also found that the neutrophil elastase-mediated effects on tumor growth are not specific to our model, as we observed similar reductions in tumor growth in the Lewis lung carcinoma model in wildtype (WT) and Elane −/− mice ( Supplementary Fig. 1 ).
l e t t e r s
Immunohistochemical analyses and lung lavage cell counts showed equivalent neutrophil content and distribution in LSL-K-ras-Elane −/− and LSL-K-ras-Elane +/+ mice ( Fig. 1c,g) , thereby excluding a role for neutrophil elastase in neutrophil trafficking. We also excluded the unlikely possibility that LSL-K-ras tumors produce neutrophil elastase by casein zymography (data not shown).
We identified significant reductions in tumor cell proliferation in LSL-K-ras-Elane −/− mice ( Fig. 1h,i) by Ki-67 immunohistochemistry. Immunofluorescence staining showed increased PI3K activity (enhanced phospho-Akt (pAkt) staining) in LSL-K-ras-Elane +/+ mice. However, the activity of mitogen-activated protein kinase kinase-extracellular signal-related kinase (MEK-ERK) pathway was not affected (Fig. 1j) . Proteinases can release growth factors sequestered within extracellular matrix for use by tumors 14, 15 , which could account for these findings. However, we were unable to detect differences between the groups for the relevant growth factors (data not shown).
We examined the possibility that neutrophil elastase could directly induce tumor cell proliferation and performed coculture experiments with WT and Elane −/− PMN to demonstrate an essential requirement for neutrophil elastase in polymorphonuclear cell (PMN)-mediated tumor cell proliferation ( Fig. 2a) . Neutrophils only release ~2% of their neutrophil elastase content upon activation, resulting in modest concentrations (~50 nM) just beyond the cell surface 16 . Dose-response curves in LSL-K-ras tumor-derived cell lines ( Fig. 2b) confirmed that modest concentrations of neutrophil elastase (40-80 nM) induced cellular proliferation, whereas excessive concentrations (~400 nM) caused cell death ( Fig. 2b) . We reproduced neutrophil elastase-induced proliferation in two human lung adenocarcinoma cell lines, A549 (which possesses K-ras mutation) and 201T (with no K-ras mutation) ( Fig. 2c-e ). The effects of neutrophil elastase required catalytic activity, as inactive neutrophil elastase (either heated or inhibited by a synthetic inhibitor (phenylmethanesulfonylfluoride, PMSF) failed to induce proliferation ( Supplementary Fig. 2 ).
Using inhibitors of the PI3K pathway (LY294002) and of the MEK-ERK pathway (U0126), we demonstrated that neutrophil elastaseinduced proliferation depends on PI3K but not on MEK-ERK ( Fig. 2f) . Neutrophil elastase exposure induced phosphorylation of Akt ( Fig. 2g) , as expected for a PI3K-dependent process. Production of phospho-MEK/ERK (determined by blotting with antibody to phospho-p44/42 mitogen-activated protein kinase (MAPK)) was not affected (Fig. 2h) .
We used Alexa Fluor 488-labeled neutrophil elastase to identify the site of neutrophil elastase and tumor cell interaction. To our surprise, neutrophil elastase gained access to the inside of tumor cells. The enzyme localized to early endosomal antigen-1 + endosomes (but not calveolae) ( Fig. 2i) , which are known to shuttle cargo from clathrin pits to other cellular locations 17 . Endosomal neutrophil elastase was required for cell proliferation, as inhibition of endosome formation (by dynasore 18 ) prevented proliferation ( Fig. 2j) . Of the growth factors known to activate PI3K, the PDGF-PDGFR complex is an attractive candidate to drive tumor cell proliferation. It is a potent inducer of pAkt via PI3K and is not found in lung epithelial cells but is highly expressed in non-small-cell lung cancer (NSCLC) 19 . Both the ligand and the receptor are produced in NSCLC, thereby creating a potent autocrine loop for PI3K activation. LSL-K-ras tumors also express PDGF and PDGFR ( Fig. 3a) .
Treating A549 cells with neutrophil elastase at cell-proliferative concentrations did not alter the quantity of PDGF, PDGFR or pPDGFR (Fig. 3b) . Neutrophil elastase exposure did increase interaction (coimmunoprecipitation) between the p85 subunit of PI3K and PDGFR ( Fig. 3c,d) . Gene silencing confirmed the dependence of neutrophil elastase-induced proliferation on PDGFR (Fig. 3e,f) .
The PI3K axis is uniquely regulated within each cell type 20 . We reasoned that neutrophils elastase must degrade a homeostatic binding partner of p85. The loss of such a binding partner would create an opportunity for PDGF-PDGFR to recruit and activate p85. We identified a number of potential neutrophil elastase substrates within the PI3K pathway, including IRS-1, an adaptor protein known to bind p85 (ref. 21) . In fact, IRS-1 and PDGF have been shown to differentially regulate PI3K activity in adipocytes, generating opposing effects on cell behavior despite activating the same p85 subunit 22 . Neutrophil elastase rapidly hydrolyzed IRS-1 at 1:100 molar concentrations ( Fig. 4a) . Cell-proliferative concentrations of neutrophil elastase eliminated IRS-1 within A549 cells (Fig. 4b) . Silencing of IRS1 gene expression in A549 cells induced tumor cell proliferation (Fig. 4c) . Marked IRS-1 overexpression reduced tumor cell growth and abrogated the proliferative effects of neutrophil elastase (Fig. 4d) , confirming that IRS-1 loss is a required event in this process. Hence, independently of neutrophil elastase, IRS-1 is capable of regulating tumor cell proliferation.
IRS-1 is not located on the cell surface, nor is it sequestered in the extracellular matrix. Therefore, neutrophil elastase-IRS-1 interaction must occur within the cell, a distinct possibility given our trafficking studies (Fig. 2i) . Confocal microscopy of neutrophil elastaseexposed A549 cells showed colocalization of neutrophil elastase and IRS-1 within tumor cells ( Fig. 4e) . Notably, IRS-1 protein abundance was significantly lower in LSL-K-ras-Elane +/+ tumors compared to LSL-K-ras-Elane −/− tumors in vivo (Fig. 4f,g) . However, Irs1 messenger RNA levels were equivalent between the two groups, as determined by quantitative PCR (Fig. 4h) , consistent with degradation of the protein.
IRS-1 has been reported to function in both protumor and prohost capacities 23 . The phosphorylation status of IRS-1 may dictate its behavior, with tyrosine-phosphorylated IRS-1 functioning as a positive effector of growth factor and serine-phosphorylated IRS-1 functioning as a regulatory factor 24 . The IRS-1 that accumulated in LSL-K-ras-Elane −/− tumors was predominantly phosphorylated on Ser307 (Fig. 4i) , consistent with this hypothesis.
It was reported that IRS-1 staining was absent in 43.6% of stage I NSCLC, correlating with a larger tumor size 25 . We performed neutrophil elastase and IRS-1 immunohistochemistry on 38 human lung adenocarcinomas to confirm an inverse relationship between neutrophil elastase and IRS-1 (Fig. 4j) . We used likelihood ratio tests of discordance and found that the proportion of discordant views (neutrophil elastase and IRS-1 were considered discordant when either one was present but the other was absent or faint in the same view) was statistically significant (P < 0.001).
These results may partially explain the PI3K hyperactivity in NSCLC despite the infrequent mutation in phosphatase and tensin homolog, the constitutive negative repressor of PI3K 20 . Our findings suggest that IRS-1 is a key regulator of PI3K. We propose that the downstream consequences of p85 binding by IRS-1 are fundamentally different (more homeostatic) than those for potent growth factors such as PDGFR. If IRS-1 were depleted (by neutrophil elastase-mediated degradation), or the ability of IRS-1 to bind to p85 were altered (for example, by the G972R polymorphism 26 ), increased cancer susceptibility might result. In fact, G972R confers increased prostate cancer risk 27 . The presence of aberrant autocrine loops (PDGF-PDGFR) would be required to substantially skew the net function of PI3K in l e t t e r s the presence of neutrophil elastase. Consistent with this hypothesis, neutrophil elastase did not induce proliferation in lung epithelial cells (which do not express PDGFR) but did in fibroblasts (which do express PDGFR) (Supplementary Fig. 3) . Neutrophil elastase exists within neutrophil azurophil granules for rapid transit to phagolysosomes, where it kills bacteria during acute infection 12, 13 . If 'dumped' into the extracellular matrix, neutrophil elastase causes tissue destruction. In the lung, unopposed neutrophil elastase degrades elastin, resulting in emphysema 28 . Neutrophil elastase may also cause cell death at high concentrations, but these concentrations are probably not achievable in vivo. We have found here that at physiological concentrations neutrophil elastase is actively transported to a subcellular location and increased cell proliferation. This ability of a secreted proteinase to enter another cell and alter cell signaling represents a new concept in proteinase biology and expands the list of both potential substrates and potential functions for proteinases.
Small-molecule inhibitors of neutrophil elastase have been developed for, although never adequately tested in, chronic obstructive pulmonary disease. To show the plausibility of neutrophil elastase inhibition as cancer therapy, we treated LSL-K-ras mice with the neutrophil elastase inhibitor ONO-5046 or vehicle for 14 weeks after AdenoCre transduction. Administration of the inhibitor reduced lung tumor growth by 69% (P < 0.05) (Supplementary Fig. 4) . The results presented here might spur testing of these agents in NSCLC, especially in light of the recent finding that emphysema predisposes individuals to lung cancer 29, 30 . Neutrophil elastase may explain the link between the two diseases. As neutrophils and neutrophil elastase are recruited to the lungs of smokers to promote emphysema, subclinical nodules may become more aggressive. Thus, neutrophil elastase inhibition might be an attractive approach to treat both diseases, which currently account for ~300,000 deaths per year in the United States alone 1, 31 .
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Note: Supplementary information is available on the Nature Medicine website.
